''' Renzapride is a full serotonin 5-HT₄ receptor agonist, partial serotonin 5-HT₃ receptor antagonist.

Clinical Uses

It is currently in late-stage clinical development for both the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and irritable bowel syndrome with alternating stool pattern (IBS-A).